

# Index

**Note:** Page numbers followed by an *f* refer to figures. Page numbers followed by a *t* refer to tables. Page numbers in **bold** indicate an in-depth discussion.

## A

- A1C (hemoglobin A<sub>1c</sub>), 2
  - premixed insulin products, 15
  - type 1 diabetes (T1D), 28, 29
  - type 2 diabetes (T2D), 33, 34*f*, 35*f*
- absorption, insulin, 23–24
- adipose, 1, 23
- Admelog, 10
- Afrezza (inhalable human insulin powder), 8*t*, 10–11, 10*f*, 18*t*
- albumin, 12
- amino acid sequence, 4
- aspart, 7, 8*t*, 10, 15, 16*t*, 18, 21

**B**

Basaglar, 12

basal insulin, 3

hypoglycemia, 44

type 1 diabetes (T1D), 30

type 2 diabetes (T2D), 33, 34<sup>f</sup>

weight gain, 46

**C**

carbohydrates

hypoglycemia, 45

insulin-to-carbohydrate ratio (I:C), 31

metabolism, 3

physical activity, 47

rapid-acting analogs (RAAs), 28

type 1 diabetes (T1D), 21, 30

β-cells

type 1 diabetes (T1D), 27

type 2 diabetes (T2D), 3–4, 44

chronic obstructive pulmonary disease, 11

continuous glucose monitor (CGM)

CSII, 20

hypoglycemia, 46

type 1 diabetes (T1D), 30, 32

continuous subcutaneous insulin infusion (CSII, insulin pump),

**20–22**, 21<sup>f</sup>, 22<sup>f</sup>, 28, 29, 37

correction doses, type 1 diabetes (T1D), 31–32

cortisol, 4<sup>f</sup>

**D**

dawn phenomenon, 4<sup>f</sup>

degludec (U-100,U-200), 8–10, 8<sup>t</sup>, **13–14**, 15, 16<sup>t</sup>, 18, 20, 44

detemir, **12–13**, 18, 44

Diabetes Control and Complications Trial (DCCT), 28

DPP-4i, 35*f*

## E

education, **49–50**, 51*t*–53*t*

1800 Rule, 31–32

euglycemia, 3

European Association for the Study of Diabetes (EASD), 33

## F

fasting plasma glucose (FPG), 27, 34*f*

Fiasp (faster acting insulin aspart product), 8*t*, 10, 18

500 Rule, 31

Food and Drug Administration (FDA), 8–10

four injections per day, **39–42**, 40*f*, 41*f*

## G

glargine (U-100), 8*t*, 9*f*, **12**, 18, 31, 32

glargine (U-300), 9*f*, **13**, 18, 20

glucagon, 45

glucagon-like peptide 1 receptor agonists (GLP-1 receptor agonists), 15

    type 2 diabetes (T2D), 33, 34*f*, 35*f*

    weight gain, 47

glulisine, 7, 8*t*, 9, 18, 21

growth hormone, 4*f*

## H

Humalog, 10

hyperglycemia, 3

    physical activity, 47

    type 1 diabetes (T1D), 30

## hypoglycemia, 1

- four injections per day, 42
- insulin degludec, 14
- insulin glargine (U-300), 13
- intramuscular administration (IM), 22
- neutral protamine Hagedorn (NPH), 11
- physical activity, 47
- symptoms, 45*t*
- three injections per day, 41
- type 1 diabetes (T1D), 29, **44–45**
- type 2 diabetes (T2D), 33, 34*f*, 45
- U-100, 12
- unawareness, **46**
- weight gain, **46**

## I

### injection therapies, **22–23**, 23*f*

- four injections per day, **39–42**, 40*f*, 41*f*
- three injections per day, **38–39**, 39*f*
- two injections per day, **37**, 38*f*
- type 2 diabetes (T2D), 33, 34*f*, 35*f*

### insulin, 4, 5*f*

- absorption, **23–24**
- administration and use, **17–25**, 18*t*
- available products, **7–15**, 16*t*, 18*t*
- basic pharmacology, **3–5**
- correction doses, 31–32
- delivery methods, 17–22, 19*f*, 21*f*, 22*f*
- education, **49–50**, 51*t*–53*t*
- injection therapies, **22–23**, 23*f*
  - four injections per day, **39–42**, 40*f*, 41*f*
  - three injections per day, **38–39**, 39*f*
  - two injections per day, **37**, 38*f*

- recommended use, **27–32**
- storage of, 18*t*, **25**
- weight gain, 46–47
- insulin aspart, 7, 8*t*, 10, 15, 16*t*, 18, 21
- insulin degludec (U-100, U-200), 8–10, 8*t*, **13–14**,  
15, 16*t*, 18, 20, 44
- insulin detemir, **12–13**, 18, 44
- insulin glargine (U-100), 8*t*, 9*f*, **12**, 18, 31, 32
- insulin glargine (U-300), 9*f*, **13**, 18, 20
- insulin glulisine, 7, 8*t*, 18, 21
- insulin lispro, 7, 8, 8*t*, 15, 16*t*, 18, 21
- insulin pump (continuous subcutaneous insulin infusion),  
20–22, 21*f*, 22*f*, 28, 29, 37
- insulin sensitizers, 45
- insulin-to-carbohydrate ratio (I:C), **31**
- intermediate-acting insulin, 8*t*, **11–12**
- intramuscular administration (IM), 22–23
- islets of Langerhans, 3
- isophane, 8*t*, 11–12

## L

- Lantus, 12
- lipids, 3
- lipoatrophy, 23
- lipohypertrophy, 23–24
- lispro, 7, 8, 8*t*, 15, 16*t*, 18, 21
- long-acting insulin, **12–15**, 25, 28
- lysine, 14

## M

- metformin, 35*f*
- multiple daily injections (MDIs), 28, 37

## N

neutral protamine Hagedorn (NPH), 8*t*, **11–12**

four injections per day, 39–42, 40*f*

storage, 25

three injections per day, 38–39, 39*f*

two injections per day, 37, 38*f*

type 2 diabetes (T2D), 44

niacinamide, 10

NovoLog, 10

## O

obesity, 23

overdose, 14

## P

pens, 18*t*, 19*f*, **20**, 25, 44

phenol, 14

physical activity, **47**

polydipsia, 33, 34*f*

polyuria, 33, 34*f*

pramlintide, 47

prandial insulin

hypoglycemia, 44

physical activity, 47

type 1 diabetes (T1D), 30

type 2 diabetes (T2D), 33, 34*f*

premixed insulin products, **15**, 16*t*

protamine, 11

protein, 3

## R

rapid-acting analogs (RAAs), **7–11**, 8*t*, 9*f*

CSII, 21

- four injections per day, 39–41, 40*f*
- premixed insulin products, 15, 16*t*
- storage, 25
- three injections per day, 38–39
- two injections per day, 37, 38*f*
- type 1 diabetes (T1D), 28, 31
- recombinant DNA, 4
- regular human insulin (RHI), 8, 8*t*, 11, 18
- ReliOn, 11, 12
- RHI (regular human insulin), 8, 8*t*, 11, 18

## S

- self-monitoring of blood glucose (SMBG), 2
  - education, 49
  - hypoglycemia, 46
  - physical activity, 47
- SGLT2i, 35*f*, 47
- short-acting insulin, 8*t*, **11**
  - four injections per day, 41–42, 41*f*
  - storage, 25
  - three injections per day, 38–39
  - two injections per day, 37, 38*f*
- subcutaneous administration (SC)
  - CSII, 20
  - Fiasp, 10
  - insulin absorption, 23–24
  - insulin degludec (U-100), 14
  - insulin degludec (U-200), 14
  - insulin glargine (U-100), 31
  - insulin lispro, 8
  - RHI, 11
- sulfonylurea (SU), 35*f*, 45
- syringes, 19*f*, **20**
  - type 2 diabetes (T2D), 44

**T**

- thiazolidinediones, 45
- three injections per day, **38–39**, 39*f*
- threonine, 12
- two injections per day, **37**, 38*f*
- type 1 diabetes (T1D), 1, 2
  - CSII, 20–21
  - 1800 Rule, 31–32
  - Fiasp, 10
  - glucose, 3
  - glycemic goals, **28–29**, 29*t*
  - hypoglycemia, 44–45
    - unawareness, 46
  - inhalable human insulin powder, 10
- insulin
  - absorption, 24
  - correction doses, **31–32**
  - initiation, **30–31**
  - ongoing adjustment, 32
  - recommended use, **27–32**
- physical activity, 47
- weight gain, 46–47
- type 2 diabetes (T2D), 1, 2
  - $\beta$ -cells, 3–4
  - Fiasp, 10
  - hypoglycemia, 45
  - inhalable human insulin powder, 10
  - injection therapies, 33, 34*f*, 35*f*
    - three injections per day, 38–39, 39*f*
- insulin
  - absorption, 24
  - barriers, **43–44**
  - recommended use, **33**, 34*f*, 35*f*



- physical activity, 47
- regular insulin (U-500), 15
- weight gain, 46–47
- T2D, 35<sup>f</sup>

## U

- U-500 (regular insulin), 7, 8<sup>t</sup>, **14–15**, 18

## V

- V-Go patch pump, 20
- vials, **20**, 25

## W

- weight gain
  - insulin, **46–47**
  - premixed insulin products, 15
  - type 1 diabetes (T1D), 1, 46–47
  - type 2 diabetes (T2D), 46–47
- weight loss, type 2 diabetes (T2D), 33, 34<sup>f</sup>